II. Indications
- Substance Dependence (especially with history of relapse)
- Alcoholism
- Best used with an aftercare program
- However, may be started in patients who are continuing to drink
- Opioid Dependence
- Patients must abstain from Opioids for at least 7-10 days before starting
- Alcoholism
- Low dose Naltrexone (0.5 mg to 4.5 mg/day) has also been proprosed for various conditions including Chronic Pain
- No rigorous evidence of benefit at these low doses and for these varied conditions, but unlikely to cause harm
- Postulated to up-regulate Opioid receptors, increas endorphin production and act as Analgesic and antiinflammatory
- May cause Opioid Withdrawal if used soon after last use of Opioids
- (2020) Presc Lett 27(4): 22
- Toljan (2018) Med Sci 6(4): 82 [PubMed]
III. Contraindications
IV. Mechanism
- Very long acting opioid Antagonist (duration >24 hours)
- Reduces Alcohol craving
- Decreases impulsive use of Opioids
V. Medications
- Naltrexone Oral Tablet (Revia)
- Naltrexone Extended Release IM (Vivitrol)
VI. Dosing
- Frequency options
- Oral Daily
- Naltrexone 50 mg orally daily (dosing range 25 to 100 mg orally daily)
- Oral Alternate days
- Naltrexone 100 mg orally on Monday, Wednesday and Friday
- IM Monthly (expensive - as much as $1300 per month in 2017)
- Vivitrol 380 mg injection every 4 weeks (appears less effective than oral dosing)
- Oral Daily
- Duration
- May need to be used for 1 year or longer
VII. Adverse Effects
- Adverse Effects decreased with IM formulation
- Hepatotoxicity (dose dependent)
- Nausea or Vomiting (10%)
- Abominal pain or cramping
- Headache
- Dizziness
- Fatigue
- Insomnia
- Sedation
- Anxiety
- Arthralgias or myalgias
- Injection Site Reaction (IM, Vivitrol)
- Risk of lethal Opioid Overdose on relapse
- Decreased Opioid tolerance after use
- No toxicity if drinking with Naltrexone
- Not indicated to make them social drinkers
- Alcoholics tend to get less drunk on Naltrexone
- Very broad safety profile with minimal adverse effects
- However, Opioid use is a contraindication
- Hepatotoxicity, however is a risk
- Croop (1997) Arch Gen Psych 54:1130-5 [PubMed]
VIII. Safety
- Pregnancy Category C
- Lactation: Unknown
IX. Efficacy
- Initial studies showed relapse reduction by 50%
- IM monthly Naltrexone injection (Vivitrol) appears more effective and with fewer adverse effects than oral daily (Revia)
- Return to Alcohol use 150 days for IM (50 days for oral)
- Leighty (2019) Mental Health Clin 9(6): 392-6 [PubMed]
- Decreases heavy drinking days
- Some studies have shown marginal benefit with Naltrexone
- Relapse rate: 38% at 13 weeks (44% with Placebo)
- Compliance rate low: 42-44% in all groups
- Krystal (2001) N Engl J Med 345:1734-9 [PubMed]
X. Monitoring
- IM Naltrexone patients should have a medic alert card
- Consult pain management in patients with Acute Severe Pain
- Obtain serum liver transaminases periodically
- Baseline
- Repeat at 3 months, then every 3-6 months
XI. Drug Interactions
- May be used in combination with other agents used in Substance Abuse
- Examples: Acomprosate, Topiramate, Gabapentin
-
Opioids
- Severe withdrawal risk (see contraindications as above)
XII. Resources
- Naltrexone Tablet (DailyMed)
- Naltrexone IM Injection (DailyMed)
Images: Related links to external sites (from Bing)
Related Studies
naltrexone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NALTREXONE 50 MG TABLET | Generic | $0.65 each |
vivitrol (on 4/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VIVITROL 380 MG VIAL | $1,446.85 each | |
VIVITROL 380 MG VIAL-DILUENT | $1,446.85 each |